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1. Introduction 
Pancreatic cancer is one of the tumors with worst prognosis. Its low survival rate is due to 
late diagnosis because of the lack of symptoms when the tumor initiates, being frequently 
diagnosed when it metastasizes to other organs. Thus, new early diagnostic biomarkers are 
an urgent need to improve pancreatic cancer survival rates. Aberrant protein glycosylation 
is common in tumoral cells, involving changes in glycosyltransferases and glycosidases that 
could be mediated by inflammatory cytokines and growth factors. These alterations are 
functionally important in cancer progression influencing cell migration and adhesion, 
metastatic capability and immune escape. These changes in protein glycosylation during 
tumor progression can lead to alterations in membrane proteins clustering and lectin 
binding, conferring functional advantages to tumoral cells. In this regard, differential 
reactivity towards endogenous lectins, especially galectins, has been reported in several 
cancers. Galectins are involved in a variety of biological processes including tumor growth 
and malignant transformation. This chapter focuses on the specific alterations in protein 
glycosylation and galectin expression and binding during pancreatic cancer progression, as 
well as their potential use as prognostic biomarkers and therapeutic targets. Interestingly, 
we have characterized the importance of the interaction between a glycoprotein (tissue 
plasminogen activator, tPA) and Galectin-1 (Gal-1) in pancreatic cancer, suggesting that 
strategies targeting this interplay might result in successful treatments.  
2. Glycosylation in cancer 
2.1 Glycans: General features 
Glycosylation is one of the most common post-translational modifications and nearly half of 
all proteins in eukaryotes are glycosylated (Spiro, 2002). Glycans (oligosaccharides from 
glycoproteins) are classified considering their linkage to the protein backbone in N-Glycans 
(bound to the amide side chain of Asn) and O-Glycans (bound to the hydroxyl of Thr  
or Ser).   
Studies focused on the carbohydrate moiety of proteins are methodologically complicated 
due to the extremely high diversity and flexibility of these structures. N-glycan content at 
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one particular site is frequently miscellaneous. Their structural diversity embraces the 
number and nature of monomeric units, their position, anomeric configuration and 
branching. Glycoproteins display site-occupancy heterogeneity (macroheterogeneity), which 
refers to the diversity on the presence or absence of glycan chains in specific aminoacids. 
Moreover, not all N-linked glycan sites are occupied. Apart from this source of variation, 
glycoproteins also present site-specific heterogeneity (microheterogeneity), which describes 
differences found regarding the carbohydrate content and structure present in a single 
glycosylation site.   
Glycosylation of proteins can affect their folding, enhance solubility, intracellular trafficking, 
localization, secretion and rate of degradation (Hakomori, 2002). Apart from conferring 
specific properties to proteins themselves, glycans significantly affect protein/protein 
interactions, preventing the non-specific ones. In this direction, they mediate accurate 
cell/cell communication and signal transduction as well as the interaction between a cell 
and the extracellular milieu and soluble signaling molecules. Carbohydrate structures are 
key in many cell biological functions and indeed eighteen different types of congenital 
disorders of glycosylation (CDG) have been genetically defined (Freeze & Aebi, 2005).   
2.2 Altered glycosylation in cancer 
Typically, cancer has been associated with gain-of-functions in oncogenes or loss-of-function 
in tumor suppressor genes. However, there are many other mechanisms responsible for 
orchestrating all the events triggering cancer stepwise progression. In spite of the marked 
physiological glycan heterogeneity, cancer progression and metastasis have been 
characterized by significant alterations of the carbohydrate signature. Indeed, aberrant 
glycosylation is one of the cancer cell hallmarks (Varki et al., 2009), and certain structures 
are well-known markers of tumor development (Hakomori, 2002; Lau & Dennis, 2008). 
Besides, changes in glycosylation are presented not only by cancerous cells but also by cells 
surrounding the tumor (Rabinovich & Toscano, 2009). This specific pattern of glycosylation 
linked to neoplasia might affect protein functionality significantly, altering cell behavior in 
many different ways. Distinctive glycosylation profiles favor or impede interactions with 
different proteins.   
Some of the best characterized glycan specific alterations in cancer are a general increase in 
sialic acid content, an increase in glycan branching and overexpression of specific 
carbohydrate antigens like sialyl Lewis antigens (SLea and SLex) (Fig.1). The tight regulation 
of enzymes during protein glycosylation is crucial and indeed, the population of sugars 
attached to each glycosylated site depends on the cell type in which the glycoprotein is 
expressed and in the physiological status of the cell. Inflammatory cytokines and growth 
factors such as IL-1ǃ, TNF-ǂ, IL-6 and EGF, mediate changes in concentration of 
glycosyltransferases and glycosidases, altering the proportion of the glycoforms present in a 
particular glycoprotein.   
Glycan alterations are functionally important in cancer progression by affecting cell 
proliferation and survival, adhesion and migration, angiogenesis and metastatic capability, 
as well as the immune escape. For instance, a very common feature in cancer is the increased 
activity of ǃ1-6-N-acetylglucosaminyltransferase V (GlcNAcT-V or MGAT5), which is in 
charge of ǃ1-6 branching of both O and N-glycans. As a functional example of this fact,  
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Fig. 1. Most frequent N-glycan altered patterns observed in tumorigenesis. Common 
features of cancer glycosylation include sialylation, increased ǃ-1,6-branching, core 
fucosylation and sialyl-Lewis antigens.   
increased branching in the ǃ1 subunit of ǂ5ǃ1 integrin due to enhanced MGAT5 expression, 
inhibits integrin clustering, reducing the attachment of cancer cells to fibronectin and thus 
inducing migration (Guo et al., 2002). This enzyme is also involved in enrichment of the SLex 
group, which confers cells the ability to extravasate and metastasize. In vivo, progression of 
mammary tumors in MGAT5 knockout mice is significantly impaired (Granovsky et al., 
2000). Various factors including oncogenes as Src, Her-2/neu, H-Ras, and V-sis and known 
cancer altered signaling pathways as Ras-Raf-Ets regulate MGAT5 transcription. What still 
remains to be determined is whether changes in glycosylation are a cause or a consequence 
of transformation. Cytokine regulation of glycosyltransferase activity suggests that signaling 
from the tumor microenvironment can be the responsible for cancer-associated 
glycosylation. 
2.3 Glycosylation in pancreatic cancer 
Specific alterations in pancreatic cancer glycoproteins have been described, such as 
increased N-glycan branching and increased fucosylation and sialylation (Zhao et al., 2007). 
Importantly, some of the aberrantly glycosylated proteins have been suggested as 
biomarkers (Lacunza et al., 2007; Okuyama et al., 2006; Peracaula et al., 2008). Lectin 
antibody microarrays have been used to detect unique glycosylation patterns in pancreatic 
cancer serum in high throughput strategies (Li et al., 2009; Wu et al., 2009). These assays 
proved efficient specificity and sensitivity and shed some light in distinguishing between 
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pancreatic cancer and chronic pancreatitis, a matter that has been for long unresolved. Major 
alterations in glycan-linked gene expression associated to pancreatic cancer epithelial to 
mesenchymal transition in vitro have been also reported (Maupin et al., 2010).   
Data proposing some of the causes of altered glycosylation have emerged. Proinflammatory 
stimuli such as IFNǄ, TNFǂ and IL-1ǂ, in pancreatic cancer cells are responsible for altering 
Muc1, Muc5AC and Muc16 glycosylation in a cell type specific manner (Wu et al., 2009), and 
indeed, cytokine secretion has also been considered in pancreatic cancer diagnosis (Fearon 
et al., 1999; Wigmore et al., 2002).   
One of the current pancreatic tumor markers is the monoclonal antibody CA19-9 (Ferrone et 
al., 2006), whose epitope is the SLea antigen in gangliosides and mucins. SLea physiologically 
functions in the extravasation of lymphocytes from the bloodstream by interacting with 
selectins on endothelial cells. In accordance with these data, its expression on the surface of 
pancreatic cancer cells has been linked to metastasis spread to other tissue sites (Aubert et 
al., 2000). Nevertheless, CA19-9 generally does not have the specificity and sensitivity 
required for general screening, being frequently restricted to monitor patient’s progress after 
surgery. RNase-1 was long ago proposed as a tumor marker in pancreatic cancer but both its 
levels and its activity in serum failed in diagnosis. However, differences in glycosylation in 
this protein exist, finding neutral structures in healthy pancreas whereas charged structures 
(such as SLex and SLea antigens) and a significant increase in core fucosylation and 
sialylation are observed in pancreatic cancer (Peracaula et al., 2003). Increased core 
fucosylation is a general cancer feature and it is also common in pancreatic cancer. Serum 
haptoglobin and other acute phase proteins are also found to be more core fucosylated 
specifically in pancreatic cancer (Okuyama et al., 2006; Sarrats et al., 2010).  
3. Galectins in cancer 
3.1 The galectin family: Main features 
Galectins belong to the lectin family of proteins, which are highly evolutionary conserved 
finding their members in all animal kingdoms and even in plants, fungi and viruses. All the 
proteins of the family share two main features: high affinity for ǃ-galactosides and a well 
conserved carbohydrate recognition domain (CRD) of 130 aminoacids (Barondes et al., 
1994). However, each galectin has a specific carbohydrate binding preference, as a result of 
their ability to accommodate different saccharides attached to galactose.  
15 galectins have been described in mammals (11 of which are expressed in humans) and 
they can be structurally clustered in three groups (Fig.2): 1) Prototype galectins (1, 2, 5, 7, 10, 
11) consist of a single CRD with a short N-terminal sequence; 2) Tandem-repeat galectins (4, 
6, 8, 9) are composed of two differents CRDs joined by a short linker peptide sequence; and 
3) Chimaeric galectins (Gal-3) have an extended N-terminal tail containing a consensus nine 
aminoacid residue-repeat rich in Pro, Tyr and Gly.   
Galectins are differently distributed in animal tissue and its expression is modulated during 
differentiation and tissue development, changing in some physiological and pathological 
conditions (Yang et al., 2008), such as in cancer (Danguy et al., 2002). Galectins are secreted 
by a non-canonical pathway and display a wide variety of intra and extracellular functions.  
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Fig. 2. Galectin structural classification. Prototype galectins (Gal-1,2,5,7,10,11,13,14,15) have 
one CRD domain. Tandem repeat galectins (Gal-4,6,8,9,12) are composed of two different 
CRD. The only chimaeric galectin (Gal-3) has an extended N-terminal domain.   
3.2 Gal-1: Structure and functions 
The first protein discovered in the human galectin family was Gal-1 (Couraud et al., 1989; 
Gitt & Barondes, 1986), which is encoded by LGALS1 gene located in chromosome 22q12-
13.1. Splicing of its four exons results in a 0.6 Kb transcript that is translated into a protein of 
135 aminoacids, without suffering any post-translational modification. Gal-1 expression 
might be modulated by histone acetylation and promoter methylation.   
Gal-1 is a symmetrical dimer of 14.5 KDa subunits and it has a ǃ-sandwich “jelly-roll” 
conformation involving two parallel ǃ-sheets, which form a central hydrophobic core 
holding both amino and carboxy-terminus of each monomer. Gal-1 CRD has a binding 
grove that allows the presence of a tetrasaccharide (A, B, C and D). C site includes the eight 
 
Fig. 3. Human dimeric Gal-1 jelly-roll structure complexed with lactose. Ribbon diagram 
prepared with MOLSCRIPT. Five-stranded (F) and six-stranded (S) sheets of each monomer 
are labelled in the image and the aminoacids involved in lactose binding are highlighted in 
the enlargement (His44, Asn46, Arg48, His52, Asn61, Trp68, Glu71 and Arg73). Adapted 
from (Lopez-Lucendo et al., 2004).  
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so well conserved aminoacids responsible for galactose binding (Fig.3), and this is common 
among all galectins. The rest of the sites are involved in galectin recognition specificity. Both 
Gal-1 and Gal-3 typically lodge a terminal LacNAc in site C-D but binding is inhibited by 
the presence of NeuAcǂ2-6 in the galactose located in B. Functional differences and binding 
avidities between Gal-1 and Gal-3 suggest the existence of additional determinants of 
binding specificity.   
Gal-1 is found in the cytoplasm, membrane, extracellular matrix (ECM) and nucleus, being 
involved in a wide variety of cellular functions through its ability to recognize many 
different proteins (Elola et al., 2005). Extracellular functions depend on Gal-1 lectin activity 
whereas intracellular functions are usually independent and involve protein/protein 
interactions.  
3.3 Role of galectins in cancer  
Galectins have been reported to be clear modulators of tumor progression (Liu & 
Rabinovich, 2005) and their heightened expression usually correlates with tumor clinical 
aggressiveness and metastasis. Several members of the family have been involved in 
tumor progression, being Gal-1 and Gal-3 the best characterized ones (Danguy et al., 2002; 
Yang et al., 2008). These proteins display important functions in several aspects of cancer 
biology including cell adhesion, migration, tumor transformation, apoptosis, cell cycle 
progression, angiogenesis and immune response regulation. Indeed, galectin inhibitors 
have been well considered for cancer therapy (John et al., 2003; Sorme et al., 2003; Zou et 
al., 2005).  
Gal-1 expression has been identified as a prognostic factor for tumor progression in many 
different neoplasms (Demydenko & Berest, 2009). Gal-1 involvement in tumor progression 
is focused on different aspects: neoplastic transformation, tumor cell proliferation and 
survival, angiogenesis, metastasis and evasion from the immune response (Fig.4).   
Inhibition of Gal-1 expression impairs transformation in glioma cells (Yamaoka et al., 2000). 
Among all Gal-1 partners, H-Ras could be the one closer linked to tumor transformation 
(Paz et al., 2001) although this interaction is lectin independent. Gal-1 is also very important 
in fibroblast activation in different tumor settings (Fitzner et al., 2005; Masamune et al., 
2006), and indeed, Gal-1 knockdown in cancer associated fibroblasts inhibits in vivo tumor 
progression (Wu et al., 2011).  
Gal-1 effects in cell proliferation are controversial. It is mitogenic in several cell types, such 
as in mammalian vascular cells and hepatic stellate cells, but it is also able to hamper cell 
growth in other cell types, such as in stromal bone marrow cells. Intracellular Gal-1 can 
induce not only cell cycle arrest but also apoptosis in cancer cells. Gal-1 concentration seems 
to be key when deciding the final outcome: high doses (μM) of Gal-1 inhibit cell 
proliferation independently of its lectin activity whereas low doses (nM) are mitogenic 
through its ability to recognize carbohydrates (Adams et al., 1996). Apart from this dose 
response effect, the cell type and cell activation status, the distribution of monomeric versus 
dimeric forms and Gal-1 compartimentalization, might be also affecting the overall result on 
cell cycle progression.   
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Fig. 4. Gal-1 is involved in many different tumor progression events. Gal-1 participates in 
cell transformation, proliferation, adhesion, migration, angiogenesis and T cell apoptosis.  
Gal-1 has been actively involved in the long range dissemination of tumoral cells or 
metastasis (Camby et al., 2006), as it participates in adhesion, migration, motility and 
invasion. Gal-1 can decrease tumor cell adhesion to the ECM, resulting in cell detachment 
from primary sites and invasion. Alternatively, the dimeric nature of Gal-1 allows 
crosslinking integrins on the cell surface of tumoral cells to proteins on the ECM, mediates 
tumoral cell/cell interactions favoring aggregation and their interaction with endothelial 
cells, facilitating tumor cell dispersion on the blood stream and establishment at distal sites 
during metastasis. In addition, Gal-1 has been also involved in invasion through adhesion 
independent mechanisms by upregulating well known ECM degradators like MMP-2, 
MMP-9, or by reorganizing the actin cytoskeleton through Cdc42 or RhoA upregulation.   
Gal-1 also plays a key role in angiogenesis as it is able to stimulate the growth of vascular 
endothelial cells. The lectin is overexpressed in activated tumor endothelium and it is 
involved in endothelial cell function (by NRP-1 interaction and VEGFR-2 activation). Gal-1 
deficiency impairs tumor growth and angiogenesis in vivo (Le Mercier et al., 2009; Thijssen 
et al., 2006). Moreover, Gal-1 modulates the expression of BEX2 and several hypoxia related 
genes involved in angiogenesis. Paracrine mechanisms involving the uptake by endothelial 
cells of Gal-1 secreted from tumoral cells have been linked to endothelial cell activation and 
tumor angiogenesis stimulation, through Ras and Erk1/2 activation (Thijssen et al., 2010).   
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Finally, Gal-1 is involved in the tumor immune response promoting an immunosuppressive 
environment at tumor sites by inhibiting full T cell activation, triggering T cell growth arrest 
and apoptosis and protecting the tumor by negatively regulating Th1 and proinflammatory 
cytokines. These effects are mediated by Gal-1 recognition of cell surface glycoproteins 
present on T cell membranes such as CD2, CD3, CD7, CD43 and CD45 (Galvan et al., 2000; 
Pace et al., 1999).  
3.4 Galectins in pancreatic cancer  
In pancreatic cancer, Gal-1 and Gal-3 are found to be overexpressed (Berberat et al., 2001; 
Chung et al., 2008; Grutzmann et al., 2004; Schaffert et al., 1998).   
Gal-3 expression is faint in ductal cells of normal pancreas but it is high in intrapapillary 
mucin neoplasms, chronic pancretatitis, cancerous pancreatic tissue and metastatic cells, 
suggesting its role in cancer cell proliferation and metastasis formation. However, decreased 
Gal-3 expression has been linked to advanced stage, tumor de-differentiation and metastasis 
in ductal adenocarcinomas, implying a fine tuned regulation of its levels in different steps of 
tumor progression. Gal-3 secreted by pancreatic cells plays a role in pancreatic stellate cell 
proliferation and in pancreatic cancer cell proliferation and invasion in vitro. A negative 
correlation between anoikis and Gal-3 presence has been established, too. Besides, the 
interaction between Gal-3 and Muc4 has been proven to be functional to dock tumor cells to 
the endothelial surface, what might present a possible mechanism to explain Gal-3 
involvement in metastasis.   
Gal-1 has found to be overexpressed in pancreatic tumors compared to normal tissue 
(Berberat et al., 2001; Grutzmann et al., 2004; Iacobuzio-Donahue et al., 2003; Shen et al., 
2004) (Fig.5). Interestingly, its expression levels correlate not only with histology but also 
with T stage, N stage and global AJCC stage of pancreatic cancer disease (Chung et al., 
2008), suggesting that Gal-1 might also participate in tumor progression and that its 
presence does not seem to be a random event. Gal-1 expression by immunohistochemical 
analysis has been reported to be mainly restricted to the ECM and fibroblasts in and around 
the cancer mass, but not to pancreatic cancer cells, suggesting its importance in the so 
characteristic desmoplastic reaction. Gal-1 is also found in the stroma of PanIN-2 and 
PanIN-3 (Pan et al., 2009) and in chronic pancreatitis (Wang et al., 2000).   
 
Fig. 5. Gal-1 is overexpressed in precursor lesions and pancreatic cancer. Gal-1 
immunohistochemistry in mouse pancreatic normal tissue, in Ela-1-myc pancreatic ductal 
adenocarcinoma (PDA) lesions and in human pancreatic cancer tissue. Scale bars 
correspond to 200 μm.  
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Interestingly, although Gal-1 did not appear in the list of genes consistently misregulated in 
pancreatic cancer that were gathered in 12 core signaling pathways (Jones et al., 2008), 54 of 
the genes found overexpressed encoded secreted or cell surface proteins, putative and 
already known Gal-1 binding targets, like laminin. Thus, Gal-1 overexpression might be 
involved in the functional outcome of these overrepresented molecules, playing a role in 
some of the key identified signaling pathways such as homophilic cell adhesion, integrin 
signaling and regulation of invasion. Gal-1 could have been excluded from the reported list 
because this important global genomic analysis was based on tumoral epithelial cells, 
leaving out the stroma, whose population seems to be the one predominantly affected by 
Gal-1 increased levels.  
Gal-1 could be involved in tumor progression in pancreatic cancer by remodeling the ECM 
in the formation of the desmoplastic reaction. Indeed, Gal-1 is able to induce activation 
(increased collagen synthesis), proliferation and chemokine production (MCP-1 and CINC-
1) of pancreatic stellate cells, through Erk1/2, Jnk, NF-кB and AP-1 activation. At the same 
time, activated pancreatic stellate cells secrete Gal-1, which can be acting autocrinely and 
might be also regulating the tumor immune response (Fitzner et al., 2005; Masamune et al., 
2006).   
As it has been described above, Gal-1 displays a wide variety of biological functions which 
bring up a high degree of complexity when trying to understand its involvement in cancer. 
Thus, Gal-1 might not always tilt the balance in the same direction. In pancreatic cancer 
cells, for example, stable transfection of the tumor suppressor p16/Ink4a can induce Gal-1 
expression and its affinity for the fibronectin receptor, resulting in increased susceptibility 
towards anoikis (Andre et al., 2007). Another Gal-1 antitumoral role is presented by the fact 
that it is downregulated in gemcitabine resistant pancreatic cancer cells (Kuramitsu et al., 
2010). The ability of Gal-1 to induce opposite effects regarding proliferation and adhesion, as 
well as its reduced expression found in some tumors (Choufani et al., 1999), hint at Gal-1 as 
a double side coin and question its nature as a protumoral molecule. Many variables might 
be influencing the final outcome, such as cell type and activation status, Gal-1 levels and 
localization, as well as its quaternary structure.  
3.5 Gal-1 establishing protein/glycan interactions  
Gal-1 interactions involving its CRD domain and lectin activity are involved in many of Gal-
1 important functions (Table 1). N-glycans from cell surface glycoproteins are the major 
ligands for Gal-1 and Gal-3, although they also bind to mucins, proteoglycans and the ECM. 
Although both proteins have high affinity for ǃ-galactosides and indeed they share many 
interacting partners such as CD45, laminin, fibronectin and integrins, a fine specificity level 
results in binding differences. The general rule is that Gal-3 prefers repeating lactosamine 
units whereas Gal-1 recognizes independent lactosamine disaccharides with low affinity 
(Kd=50 μM) but deeply increases avidity when presented in multiantennary repeating units 
(Kd=5 μM) and when the lectin is surface bound to cell membranes or to the ECM. Indeed, 
Gal-1 is involved in microdomain (lattice) formation within membranes by crosslinking 
ligands in a glycoside cluster effect that greatly increases its affinity. However, as a matter of 
fact, Gal-1 is able to recognize only about 1/40 of the total N-glycans present in human 
serum glycoproteins (Kita et al., 2007), and around 1/8 of the sites supposed to be galectin 
specific. It is believed that part of Gal-1 specificity is mediated by additional binding sites 
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Gal-1 partners Biological context Functional Outcome 
CA-125 cervical cancer cells Gal-1 export to cell surface 
CD2/CD3 T cells  T cell activation and apoptosis 
CD4 T cells Unclear 
CD43, CD45 T cells Gal-1 induced T cell death (depending on 
specific receptor glycosylation). Redistribution 
of the receptors in the cell surface.  
CD7 T cells Induction of apoptosis 
CEA colon carcinoma cells Unclear 
Chondroitin 
sulphate 
SMC Incorporation of ECM components important 
for SMC 
Fibronectin placenta  
ovary carcinoma cells 
Control of cell adhesion 
1B2 glycolipid olfactory neurons Adhesion between adjacent axons and with 
the ECM resulting in olfactory axon 
fasciculation 
Glycoprotein 90K  melanoma cells Formation of multicell aggregates 
GM1 ganglioside neuroblastoma cells Sialidase dependent cell growth inhibition  
HBGp82 brain Unknown 
INTEGRINS   
ǂ1ǃ1, ǂ7ǃ1 SMC 
skeletal myocytes 
Intracellular signaling leading to adhesion, 
FAK activation, migration 
ǂ5ǃ1 colon, breast, 
ovarian, hepatocellular 
carcinoma cells, 
Antiproliferative effects, induction of anoikis  
ǂMǃ2 macrophages Possibly crosslinking receptors or affecting 
receptor-ligand binding affinity 
Laminin placenta,  
smooth muscle cells, 
leydig cells 
Assembly of ECM, adhesion, migration, 
apoptosis 
LAMP-1,  
LAMP-2 
ovarian, 
colon carcinoma cells 
Tumor cell adhesion and metastasis 
Mucin gastrointestinal tract Protection from the epithelial surface 
NRP-1 endothelial cells Signaling pathway activation, migration and 
adhesion 
Pre-B  
cell receptor 
B cells Cell differentiation, adhesion 
Osteopontin, 
vitronectin 
SMC Adhesion, ECM assembly 
Thrombospondin SMC Adhesion 
Table 1. Proteins that are known to interact with Gal-1 through their CRD. Description of the 
best characterized Gal-1 interactors, specifying the biological context in which the 
interaction has been identified, and the consequent functional outcome. SMC: smooth 
muscle cells. Detailed references can be found at (Camby et al., 2006).  
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recognizing more than the canonical galactose. Thus, the particular structural context of 
galectin binding sites depicts a complex scenario and impairs stating generalizations. For 
instance, Gal-1 is able to induce T cell death by binding a glycan ligand without 
lactosamine units, that is very abundant but less preferred (Hernandez et al., 2006). 
Normally though, Gal-1 recognition capacity is deeply influenced by specific conditions 
regarding carbohydrate content and linkage. Minor alterations in N-glycan chains have 
been reported to influence Gal-1 binding in such a way that changes the overall biological 
outcome (Andre et al., 2007). Cell type specific expression patterns of several proteins and 
their glycans can modulate different Gal-1 mediated effects (Gu et al., 1994; Moiseeva et 
al., 1999). Particular glycosylation structures are known to mask glycans to Gal-1, which 
impede Gal-1 induced T-lymphocyte (Liu & Rabinovich, 2010) and cancer cell (Valenzuela 
et al., 2007) death. For instance, in contrast to Th1 and Th17 cells, Th2 cells are protected 
from Gal-1 induced apoptosis by presenting ǂ2-6 sialylation of cell surface glycoproteins 
(Toscano et al., 2007).   
In the ECM, Gal-1 displays high affinity for laminin, fibronectin, thrombospondin, 
vitronectin, osteopontin and glycosamine glycans such as chondroitin sulfate (Table 1). 
Depending on the cell type and cell activation status, these interactions finally lead to a pro-
adhesive or an anti-adhesive effect.   
In the cell membrane, Gal-1 has many interactors resulting in very different effects (Table 1). 
Glycosylated cell surface receptors are closely linked to the adhesive properties mediated by 
Gal-1. For instance, Gal-1 interaction with ǂ7ǃ1 integrin interferes with integrin/laminin 
binding and controls cell adhesion. Gal-1 interaction with NRP-1 has been involved in 
migration and adhesion of endothelial cells (Hsieh et al., 2008). Gal-1 can also function as a 
regulator of the immune response through its interaction with CD7, CD45 and CD43. 
Moreover, Gal-1 has also been involved in cell growth inhibition through its interaction with 
ǂ5ǃ1 integrin, GM1 ganglioside or the glycoprotein 90K/MAC-2BP. Gal-1 can also recognize 
HBGp82 in the brain, CA125 in ovarian cancer cells, LAMP-1, LAMP-2 and CEA in colon 
carcinoma cells and 1B2 glycolipid in olfactory axons.  
4. tPA: Connecting galectins and cancer protein glycosylation? 
4.1 tPA: General features 
Our group has recently characterized how an interaction between Gal-1 and a glycosylated 
protein –tPA- is involved in pancreatic cancer progression (Roda et al., 2009). tPA is mainly 
synthesized by endothelial cells, but it has also been detected in the central nervous system, 
being secreted by neurons and glial cells and it can also be produced by keratinocytes, 
melanocytes and various tumor cells. tPA best documented role is the conversion of 
plasminogen into plasmin, which degrades fibrin clots in blood vessels after thrombosis 
through a well-orchestrated process involving several regulators. Besides, tPA is also 
involved –by its catalytic activity- in the activation of growth factors and matrix 
metalloproteinases in the ECM (Fig.6). In addition to these proteolytic activities, we and 
others have demonstrated that tPA can exert catalytic-independent functions in different cell 
types, including neurons (Medina M.G. et al., 2005), kidney fibroblasts (Hu et al., 2006) and 
tumors (Ortiz-Zapater et al., 2007).   
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Fig. 6. tPA physiological functions. The best documented role for tPA is the activation of the 
zymogen plasminogen into plasmin, which degrades fibrin clots in blood vessels after 
thrombosis. Moreover, tPA is also involved in activation of matrix metalloproteinases and 
growth factors and in the ECM degradation, participating in cell migration and tissue 
remodeling events.  
tPA is a glycoprotein of 527 aminoacids and around 70 KDa, depending on specific 
glycosylation. tPA is synthesized as a single-chain protein but it is quickly hydrolyzed by 
plasmin, forming a two-chain structure maintained together by a disulfide bond. 
Structurally, apart from a typical signal peptide and a prosequence, tPA is formed by 5 
different autonomous domains, which are encoded by separate exons or sets of exons: 1) 
The fibronectin type I domain in the amino terminus, which mediates fibrin affinity; 2) An 
EGF-like domain which is probably involved in cell surface receptor binding; 3) Two kringle 
regions with a triple looped structure, with a high degree of homology with plasminogen 
kringle domains and 4) A serine protease domain with the active site residues His322, 
Asp371 and Ser478.  
Due to the size of tPA and the presence of glycosylated chains in the molecule, the complete 
structure of the protease remains still undetermined. However, the detailed structure has 
been revealed for some of the domains by NMR or X-Ray diffraction as for the fibronectin 
type I domain (Downing et al., 1992), EGF domain (Smith et al., 1995), kringle 2 (Byeon et 
al., 1991; Byeon & Llinas, 1991; de Vos et al., 1992) and the catalytic domain (Lamba et al., 
1996; Renatus et al., 1997a; Renatus et al., 1997b).   
Glycosylation differences describe two different tPA isoforms (type I and type II), 
displaying species, cell and site-specific patterns of these post-translational modifications. In 
type I tPA, 4 glycosylation sites are occupied in separate domains, which play a role in 
different biological and pathological tPA functions: an O-linked fucose in Thr61 (EGF 
domain) and three N-linked carbohydrate chains; an oligomannosidic structure highly 
conserved between species at Asn117 (in kringle 1), and two complex and hybrid type 
structures at Asn184 (in kringle 2) and Asn448 (in the catalytic domain). Type II tPA lacks 
the glycosylation at Asn184 and this absence allows the conversion of single-chain to two-
chain tPA, through plasmin mediated cleavage of the polypeptide backbone between 
Arg275 and Ile276. The presence of glycan chains at site Asn184 affects the structure of the 
www.intechopen.com
Glycans and Galectins: Sweet New Approaches 
in Pancreatic Cancer Diagnosis and Treatment  
 
317 
glycan population at Asn448, being two-chain tPA a more active tPA regarding clot lytic 
activity and fibrin-binding capacity. 
4.2 Role of tPA and tPA receptors in pancreatic cancer 
tPA overexpression correlates with poor prognosis in several cancers. In pancreatic cancer 
studies, tPA is found to be highly expressed in well differentiated human pancreatic cancer 
cultures and overexpressed in 95% of pancreatic ductal adenocarcinomas (PDAs), being 
absent in normal pancreas (Paciucci et al., 1996, 1998; Ryu et al., 2002) (Fig.7).   
 
Fig. 7. tPA is overexpressed in human pancreatic cancer. tPA expression assessed by 
immunohistochemistry in normal pancreas (normal), showing no tPA expression, whereas, 
in human pancreatic ductal adenocarcinoma (PDA), high expression levels of tPA are 
detected in ducts.   
In vitro and in vivo studies have determined that tPA contributes to pancreatic cancer 
progression by increasing cell invasion, Erk1/2 phosphorylation, cell proliferation and 
angiogenesis (Aguilar S et al., 2004; Diaz et al., 2004; Paciucci et al., 1998). These effects are 
mediated through tPA interaction with different cell membrane receptors. In this regard, 
EGFR is overexpressed in pancreatic cancer and it has been demonstrated to participate in 
tPA effects in cell proliferation (Hurtado et al., 2007; Ortiz-Zapater et al., 2007). AnxA2 -the 
best characterized tPA receptor and its major receptor in endothelial cells- has also been 
clearly involved in tPA-mediated pancreatic cancer cell invasion, proliferation and 
angiogenesis (Diaz et al., 2004; Ortiz-Zapater et al., 2007). Nevertheless, AnxA2 does not 
seem to be the only functional tPA pancreatic cancer receptor as its interaction with the 
protease only explains part of the tPA found in the cell membrane (Diaz et al., 2004; Ortiz-
Zapater et al., 2007). These data and the fact that AnxA2 seems to be inappropriate as a 
target for pancreatic therapy due to its important physiological functions in blood 
coagulation homeostasis moved us to find new tPA receptors that could be involved in tPA 
protumoral functions in pancreatic cancer. As described in the next section, we have 
recently demonstrated that Gal-1 is a new functional tPA receptor (Roda et al., 2006, 2009). 
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4.3 tPA/Gal-1 interaction: Glycosylation involvement and role in pancreatic cancer  
Interaction between tPA and Gal-1 was first identified in total tumoral pancreatic cell lysates 
by affinity capture with tPA-sepharose followed by 2D- electrophoresis (Roda et al., 2006). 
However these data did not prove whether tPA/Gal-1 interaction was direct or mediated 
through other proteins. In a more recent work, using recombinant proteins and surface 
plasmon resonance, we proved that tPA/Gal-1 interaction was direct and specific (Roda et 
al., 2009). Furthermore, Gal-1 was able to increase tPA mediated plasmin generation, 
suggesting interesting functional outcomes from their interaction.   
Taken into account that 1) galectins are lectins with high affinity for ǃ-galactosides, 2) Gal-1 
binds galactose, and lactose with even higher affinity, through its CRD, and 3) tPA is a 
glycoprotein, we hypothesized that tPA and Gal-1 interaction was N-glycan mediated. In 
order to know whether that was the case, surface plasmon resonance was used to determine 
if carbohydrates were able to interfere with this interaction. Galactose (in a dose dependent 
manner) and lactose (with even higher effectiveness), inhibited tPA/Gal-1 interaction (Roda 
et al., 2009). Proving galactose specificity, neither glucose nor cellobiose was able to do so. 
These data demonstrated that the Gal-1 CRD was involved in tPA interaction and as 
expected, pointed at galactose in a ǃ-anomeric position as its high affinity epitope.   
Importantly, our results showed that this Gal-1/tPA interaction was not only relevant in 
vitro, but also in vivo where the lectin was actively involved in tPA induced Erk1/2 
activation, proliferation, migration and invasion. tPA/Gal-1 effects were not restricted to 
pancreatic cells but were also found in tPA-mediated protumoral effects in fibroblasts from 
the tumor stroma, demonstrating the important role for tPA/Gal-1 interaction in the 
epithelial/fibroblast crosstalk and in pancreatic cancer tumor progression (Roda et al., 2009).  
 
Fig. 8. Gal-1 is acting as a functional tPA receptor in pancreatic cell lines and fibroblasts. 
Gal-1 in pancreatic cancer cells can activate Erk1/2, induce proliferation, migration and 
invasion by binding to tPA in an autocrine fashion. Gal-1 can also act in a paracrine fashion 
over fibroblasts, triggering the same pathological effects that could be involved in the 
desmoplastic reaction.  
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Thus, we propose a model in which tPA secreted from pancreatic epithelial cells could act 
both in a paracrine and in an autocrine manner. In the latter, it would bind to Gal-1 in the 
cell surface of pancreatic tumoral cells triggering Erk1/2 activation and subsequent 
proliferation, as well as invasion. These events would be favoring tumor progression. On 
the other hand, tPA could bind in a paracrine fashion to Gal-1 from fibroblasts, what would 
induce the same events but in this mesenchymal cell line, leading to the desmoplastic 
reaction (Fig.8).   
5. Glycans and Gal-1 in pancreatic cancer diagnosis and therapy  
5.1 Glycans in diagnosis and therapy 
Serum glycoproteins constitute the most frequent family of current tumor markers (Ludwig 
& Weinstein, 2005). Among others, two main characteristics highlight glycans in diagnosis: 
their altered structure upon tumorigenesis and the fact that they are frequently found in 
secreted proteins, what might facilitate their accessibility in the clinics. The most frequently 
used glycoproteins in this context are highly glycosylated mucins like CA19-9, CA125, 
CA27-29, CA15-3 but other proteins like PSA, AFP, CEA, RNase1 and hCG-ǃ have also been 
considered (Peracaula et al., 2008).   
Glycans have been closely involved in several events driving tumor progression, so 
therapeutic strategies targeting them have been studied with special attention (Dube & 
Bertozzi, 2005; Fuster & Esko, 2005). For example, the carbohydrate moiety of growth factor 
receptors is key in the regulation of cell signaling towards proliferation. Besides, several 
molecules like mucins, proteoglycans and gangliosides, modulate growth factor receptor 
activity through their glycan structures. Thus, different approaches directed to these glycans 
have already been designed and are being tested in the clinics such as peptide-based 
vaccines and monoclonal antibodies against mucins or gangliosides. The possibility of 
altering glycan synthesis and their maduration has also been proposed. One of the most 
studied effects of glycans over tumor development is their role in invasion due to their 
structurally altered presence in proteins well known for their effects upon adhesion and 
migration like E-cadherin, integrins, syndecans, proteoglycans and hyaluronan. Therefore, 
several strategies with the aim to block tumor specific patterns of glycosylation have been 
planned such as the inhibition of GnTV (responsible of increased ǃ1,6-branched N-glycans) 
or polysialyltransferases. The reduction of tumor angiogenesis has also been addressed 
through glycan-based therapy by the use of modified heparin fragments or compounds 
inhibiting heparanase. Anti-selectin antibodies or mimetics of selectin ligands have been 
proposed to be useful against metastasis. 
5.2 Gal-1 in diagnosis and therapy 
Galectins are overexpressed in many different tumors and their expresssion has been 
related to poor prognosis suggesting their possible use as markers for diagnosis (Lahm et 
al., 2001; Rabinovich, 2005; Salatino et al., 2008). Indeed, Gal-1 detection in serum has been 
proven to be useful to monitor tumor progression and clinical severity in patients with 
head and neck squamous cell carcinoma (Saussez et al., 2008) and ovarian carcinoma 
(Allen et al., 1993).    
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In pancreatic cancer therapy, Gal-1 fulfills interesting requirements to be considered for 
targeting such as not being expressed in normal pancreas, increasing drug selectivity. 
Moreover, the use of Gal-1 inhibitors is particularly appealing because Gal-1 knockout mice 
are viable and fertile and do not show overt abnormalities (Poirier & Robertson, 1993), 
probably due to redundant functions from other members of the galectin family. 
Nevertheless, the dichotomous effects of Gal-1 must be well considered for efficient 
targeting, as depending on many intrinsic and extrinsic factors, the lectin can exert contrary 
effects (mitogenic or antiproliferative and pro or anti-adhesive). That is so the case that even 
Gal-1 and Gal-1 mimetic compounds have been also proposed for anticancer therapy 
(Fischer et al., 2005). Thus, special attention must be paid concerning Gal-1 conformation, 
quaternary structure, oxidation state, concentration, subcellular localization, ability to 
establish protein/protein or protein/glycan interactions, target cell type and presence of 
specific glycan receptors with certain glycosylation signatures, among others. Another 
interesting aspect to take into account for the use of Gal-1 in cancer therapy is its role as a 
master regulator of the immune response. Indeed, downregulating Gal-1 expression inhibits 
migration and restores susceptibility to apoptosis and so to cytotoxic drugs, making its 
inhibition a promising target in cancer therapy (Salatino et al., 2008; Rabinovich, 2005).  
Finally, it has been reported that the huge stromal reaction accompanied with an important 
lack of angiogenesis impairs drug delivery and cause pancreatic cancer resistance. The 
stroma has been shown to be decisive in tumor progression, which can be inhibited 
maintaining a normal context. Different stromal cells have been under the scope for therapy 
as they are more accessible to pharmacological agents and genetically stable, which makes 
them less prone to acquire resistance. Indeed, therapies targeting other molecules involved 
in the desmoplastic reaction and vasculature have proven to improve efficiency delivery of 
gemcitabine in a pancreatic cancer mice model (Olive et al., 2009). Interestingly, silencing 
Gal-1 results in increased chemotherapy toxicity in glioblastoma cell lines (Le Mercier et al., 
2008; Puchades et al., 2007). Gal-1 importance in tumor microenvironment 
immunosuppression is also considered in treatment. As a matter of fact, Gal-1 inhibition as 
adjuvant with vaccine immunotherapy significantly reduces breast tumor progression in 
mice (Stannard et al., 2010).  
6. Conclusion 
Overall, this context provides us with a whole universe of possibilities that might help in the 
design of new diagnosis markers and therapies directed to hamper tumor development. 
Still, the huge versatility of most of the molecules containing a glycan fraction forces 
research to deeply evaluate the molecular mechanisms affected upon targeting in order to 
avoid undesirable secondary effects that might prevent their use in treatment. Regarding 
Gal-1, the same precautions must be taken, considering the vast amount of partners and 
biological outcomes to which it is link. This complexity impairs analyzing the role of 
molecules independently and requires that each and every interaction is studied in detail. In 
this sense, a much finer approach in cancer therapy would result from targeting specific 
protein/protein interactions instead of individual proteins.  
Our work has made an important contribution by specifically deciphering the relevance of 
Gal-1 interaction with a glycosylated protein – tPA- in the context of pancreatic tumor 
progression. Our data add valuable knowledge to enable a better understanding of 
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pancreatic cancer molecular biology. The relevant functional outcomes from Gal-1/tPA 
interplay open the door to new therapeutic strategies targeting the complex without 
interfering with tPA and Gal-1 independent physiological functions. Therefore, we stand for 
tPA/Gal-1 interaction as a promising target for pancreatic cancer, which could delay or even 
revert tumoral progression in this devastating disease.  
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